Janssen’s experimental HIV vaccine regimen was found to be safe but ineffective in the Phase 3 Mosaico clinical trial: and as a result the company is discontinuing the study.
People with HIV who began taking antiretroviral therapy (ART) in the early stages of infection achieved a lengthy period of HIV suppression without ART after receiving two broadly neutralizing anti-HIV antibodies (bNAbs), according to a study published...
Curate Biosciences reports that City of Hope, one of the largest cancer research and treatment organizations in the US, has given a thumbs up to the company’s cell processing system for advanced cell separation.
Vir Biotechnology and the Bill & Melinda Gates Foundation have partnered up to develop broadly neutralizing antibodies designed to provide a ‘vaccinal effect’ for the treatment of HIV and prevention of malaria.
Johnson & Johnson has announced results from the primary analysis of its Imbokodo Phase 2b HIV vaccine clinical trial, with data showing the investigational HIV vaccine candidate did not provide sufficient protection against HIV infection. A Phase...
The online pharma event will address the COVID-19 pandemic’s impact on the industry (and vice versa) and innovation in the face of formidable challenges.
June 2021 marks the 40th anniversary of the publication of the first reported cases of AIDS in the US. A session at BIO Digital – featuring Dr. Anthony Fauci, Director of NIAID at the NIH – will focus on four decades of innovation as well as the critical...
Seasonal flu vaccines typically work 40-60% of the time, according to the US Centers for Disease Control and Prevention (CDC). An experimental recombinant protein nanoparticle vaccine that stimulates a strong immune response is hoping to address that...
Moderna will take mRNA flu and HIV vaccines into Phase 1 trials this year, as well as beginning a pivotal Phase 3 study for its cytomegalovirus (CMV) vaccine candidate.
Moderna announced today that it is expanding its pipeline of innovative vaccines with three new development programs based on the 'clinical success' of its infectious disease vaccine portfolio to date.
Sanofi and GSK announced a delay on Friday in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly, saying clinical trials showed an insufficient immune response in older people.
J&J will test a vaccine candidate for HIV prevention in 3,800 men across the US and Europe, at the same time as ViiV releases positive comparative data on its HIV treatment.
Johnson & Johnson has unveiled a vaccine facility in Leiden, the Netherlands, which will focus on R&D, technological development, and large-scale production of vaccines for late-stage clinical trials.
Panacos, a US based pharma firm, has outlined its work to identify
three new series of compounds that inhibit HIV fusion at a
different site to the only approved fusion inhibitor, Roche's
Fuzeon (enfuvirtide).
